The Chinese prostatic hyperplasia drug market is estimated to have experienced year-on-year growth of 12.6%, to reach a value of approximately CNY 3.67 billion by the end of 2012.
Benign prostatic hyperplasia (BPH) is an increase in size of the prostate. BPH involves hyperplasia of prostatic stromal and epithelial cells, resulting in the formation of large, fairly discrete nodules in the periurethral region of the prostate.
When sufficiently large, the nodules compress the urethral canal to cause partial, or sometimes virtually complete, obstruction of the urethra, which interferes with the normal flow of urine. It leads to symptoms of urinary hesitancy, frequent urination, dysuria (painful urination), increased risk of urinary tract infections, and urinary retention.
Adenomatous prostatic growth is believed to begin at approximately age 30 years. An estimated 50% of men have histologic evidence of BPH by age 50 years and 75% by age 80 years; in 40-50% of these men, BPH becomes clinically significant.
In China, the PH morbidity of men in urban regions is far higher than that in rural regions. The PH morbidity is influenced by several factors: the morbidity of married people higher than that of unmarried ones and the relatively high morbidity among patients suffering from diseases in the nervous system, respiratory system and reproductive system. The morbidity of people with a family history of PH is over 50%.
There are numerous anti-PH drug manufacturers in China. In 2011, the total market share of top 4 manufacturers of China's hospital-use anti-PH drugs by market share was 71.22%, which was slightly lower than that in 2010; the total market share of top 8 manufacturers was over 83%, with the highly-concentrated market.
Among it, Sino-US Hangzhou MSD Pharmaceutical Co., Ltd. ranked the top, accounting for over 30% of the market share in 2011.
Its primary variety is Finasteride (Proscar), accounting for over 90% of the market share in the drug variety. Developed by MSD Co., Ltd, Finasteride (Proscar) appeared in domestic market in 1993 and always tops the BPH drug market.
The prospect of China's anti-PH drug market is very bright. The annual growth rate of China's anti-PH drug market size is predicted to be over 10% in years to come.
For more information on the Chinese prostatic hyperplasia drug market, see the latest research: Chinese Prostatic Hyperplasia Drug Market
Follow us on Twitter @CandMResearch
Companiesandmarkets.com issues news updates and report summaries covering all major industries and sectors. The service provides additional client monitoring and timely alerts to breaking industry and sector news leading the day's business headlines. News articles, written by our staff, contain additional analyst insight, providing value added insight for our readers. News updates and real-time alerts on newly-released market reports are also available from our Facebook page, Twitter feed @CandMResearch and RSS links. We also welcome inquiries from business journalists and the news media.